Award type :
Product Development Award
Product Development Award
Product type :
Vaccines
Vaccines
Award year :
2022
2022
Project start date :
05 / 04 / 2022
05 / 04 / 2022
Project end date :
05 / 31 / 2024
05 / 31 / 2024
Project duration (months) :
26
26
Development stage :
Phase 1
Phase 1
Target disease :
Cholera
Cholera
Region served :
Sub-Saharan Africa
Sub-Saharan Africa
Recipient organization / Country of funding recipient organization :
International Vaccine Institute (IVI) / Republic of Korea
International Vaccine Institute (IVI) / Republic of Korea
Collaborator(s) / Country :
EuBiologics / Republic of Korea, Massachusetts General Hospital (MGH) / USA
EuBiologics / Republic of Korea, Massachusetts General Hospital (MGH) / USA
Funding amount(KRW) :
2,642,828,555
2,642,828,555
This project builds on technology transfer of a cholera conjugate vaccine (CCV) product from Massachusetts General Hospital (MGH) to EuBiologics, which was funded through a previous award. The target of this project is the production of GMP clinical trial material in several formulations to support phase I evaluation. The phase I first-in-human (FIH) study will generate exploratory data on product safety and the effect of antigen doses formulated with or without Alum adjuvant on humoral immune responses in a non-endemic population, which will provide valuable guidance on dose selection. Development of an injectable conjugated cholera vaccine is the key to improving protection in young children.